CCCC · C4 Therapeutics Inc
United States · RS rating 28 · As of 2026-10-14
| Price | 2.61 USD |
|---|---|
| 1-day change | -6.1% |
| RS rating (overall / 1M / 3M / 12M) | 28 / 9 / 13 / 78 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 35 / 35 / 46 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +59.1% |
| Sales growth Q/Q | -1.9% |
| Distance from 52-week high | +44.1% |
| Market cap (USD) | $289.8M |